mRNA Provides Significant Long-Term Investment Opportunities

Investment Insights

The success of the mRNA-based vaccine for the COVID-19 virus established that mRNA technology is highly effective in improving the body’s immune response. Messenger ribonucleic acid (mRNA) vaccines are faster and easier to mass-produce than traditional vaccines. This feature enabled biopharma companies to invest in and produce mRNA-based COVID-19 vaccines on a large scale, which was necessary to combat the pandemic. But how does one keep fundamentals over frenzy and identify the best-placed beneficiaries? And will the capital raising activity continue to remain that strong? 

Key Takeaways:
•    The mRNA vaccine technology promises a huge growth potential to biopharma companies.
•    After the recent success of mRNA vaccines to fight against the COVID-19 virus, companies are participating in M&A and fundraising activities.
•    While mRNA is still in its infancy stage, the fight against COVID-19 has served as a significant testing ground for the technology.
•    Companies are now exploring the possibility as well as the benefits of mRNA vaccines to treat other diseases.

To know more...


Related Topics

SG Analytics Whitepaper 5G, 6G, and the Next


5G, 6G, and the Next

The whitepaper on 6G technology sheds light on the future of communication networks over the coming years. It describes the upcoming need for a strong...

SG Analytics - IR - Whitepaper - The Return of Global Inflation


The Return of Global Inflation

The world economy is entering what could turn out to be a protracted period of weak growth and elevated inflation, according to the World Bank. The global...

White Paper Digital Innovations Transform Investment Research


Digital Innovations Transform Investment Research

In investment research, technology has become a key enabler providing faster access to actionable insights. Digital innovations in investment research, such...

We bring comprehensive data driven insights to everyone, everywhere